CE NVESTORCONFERENCE

bio.org/CEO • #BIOCEO19

February 11-12, 2019New York Marriott Marquis

Partnering activity is up 40%Meet more than 50 new investors and at least 150 new companies

Why Attend?• EXPERIENCE the largest, unbiased forum where institutional investors,

industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.

• HEAR Washington’s perspective on policy and other timely developments affecting the industry.

• EVALUATE fresh investment opportunities including compatible, complementary, and competitive companies.

• LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

• ATTEND Fireside Chats featuring candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2019.

• GAIN ACCESS to BIO One-on-One Partnering™ for scouting potential investments and deal partners, optimizing your time at the event.

• UNIQUE PLATFORM for your company to highlight accomplishments and discuss upcoming milestones. Approximately 190 companies will be chosen based on a selection process evaluating a company’s pipeline and R&D activities.

• GET THE PULSE of the current and proposed investment trends in biotechnology.

• NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

Now in its 21st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

CEO INVESTORCONFERENCE

1,400+ATTENDEES

768COMPANIES

158COMPANY

PRESENTATIONS

2,700+PARTNERING

MEETINGS

700REGISTERED INVESTORS

1 bio.org/CEO • #BIOCEO19

2019 AgendaSUNDAY, FEBRUARY 10

1:00 PM-5:30 PM BIO Executive Leadership Course: Improving Negotiations and Decision Making by Applying Game Theory (separate registration required)

MONDAY, FEBRUARY 11

9:00 AM-11:30 AM Company Presentations9:00 AM-9:55 AM Reshaping Tumor Microenvironments via Immunotherapies10:00 AM-10:55 AM Fireside Chat: Nancy Thornberry, Chief Executive Officer, Kallyope

11:00 AM-11:55 AM Advances in Neuromuscular Disease Treatments12:00 PM-12:55 PM Fireside Chat: Geoff Meyerson, Managing Partner and Co-Founder, Locust Walk

1:15 PM-4:15 PM Company Presentations1:30 PM-2:25 PM Navigating Payers’ Expectations for Value-Based Agreements2:30 PM-3:25 PM Fireside Chat: Jinzi J. Wu, PhD, Founder, Chairman, and Chief Executive Officer,

Ascletis Pharma Inc.

3:30 PM-4:25 PM Attacking Biological Mechanisms of Aging to Extend Healthspan4:30 PM-5:45 PM Market Outlook—Leveraging Market Corrections for M&A or IPOs6:00 PM-7:00 PM Welcome Reception

TUESDAY, FEBRUARY 12

9:00 AM-11:30 AM Company Presentations9:00 AM-9:55 AM New Treatments for Diabetes and Obesity: Innovations for Chronic Diseases10:00 AM-10:55 AM Fireside Chat: Jonathan Leff, Partner, Deerfield Management; Chairman,

Deerfield Institute; and Annette Grimaldi, Managing Director and Head of Life Sciences Investment Banking, BMO Capital Markets

11:00 AM-11:55 AM Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?

12:00 PM-12:55 PM Fireside Chat: Roger Crystal, MD, Chief Executive Officer, Opiant Pharmaceuticals

1:00 PM-1:55 PM Regulatory Changes to Cross-Border Investments: CFIUS and Biotech Deals1:15 PM-3:45 PM Company Presentations2:00 PM-2:55 PM Removing Commercialization Barriers for New Antimicrobial Drugs 3:00 PM-3:55 PM Fireside Chat: Dr. Aoife Brennan, Chief Executive Officer and Chief Medical Officer,

Synlogic, Inc.

4:00 PM-4:55 PM Are Record Levels of IPOs Still Disrupting M&A Deals?5:00 PM-6:00 PM Closing Reception

Visit bio.org/ceo for the latest schedule of events.Sessions, speakers, and presentations are subject to change.

2 bio.org/CEO • #BIOCEO19

BIO Executive Leadership Courses: Improving Negotiations and Decision Making by Applying Game TheoryOffered in conjunction with the BIO CEO & Investor Conference for an additional fee. Separate registration required.

SUNDAY, FEBRUARY 10 • 1:00-5:30 PM

This workshop is designed for executives who wish to enhance their skills in negotiations, influencing and decision making. The uniqueness of this advanced workshop is to leverage the combination of these skills. You will not only learn to anticipate but also to plan strategically ahead by making use of insights from game theory, with the aim to improve decision making and negotiation outcomes. The learnings from game theory will be applied to real-life pharma/biotech cases.

The Course will feature interactive sessions, facilitated discussions and in-class exercises, this workshop is primarily based on real-life pharma/biotech cases. The cases will be analyzed by uniquely combining the ideas of game theory and advanced business development practice.

• Learning ObjectivesBy participating in this workshop, you will learn how to:

• Improve your decision making by acquire a systematic framework for decision making using Game Theory.• Achieve better negotiation results by applying advanced negotiation techniques.• Enhance your influencing skills by applying learnings from the BD practice.• Master new strategies to steer business interactions.

• Faculty

Harm-Jan Borgeld, CSAP, PhD Head Alliance Management Merck KGaA, Darmstadt, Germany

Stefanie Schubert, CA-AM, PhD Professor of Economics SRH University Heidelberg

• Topics CoveredDecision making

• Successful CEOs decision making• Parallel option assessment• Influencers of rationale decision making

Negotiations

• First and second offer strategies• Multiple Equivalent Simultaneous Offers• Know when not to negotiate• The Right Rationale• Sources of Negotiation Power• Group negotiations

Influencing

• Traits of success influencers• How to weaken your opponent’s

strategic moves• Influencing in the business environment

3 bio.org/CEO • #BIOCEO19

MONDAY, FEBRUARY 11

• Reshaping Tumor Microenvironments via Immunotherapies9:00-9:55 AM

Current CAR-T therapies have shown significant benefits attacking hematological malignancies, and currently approved checkpoint inhibitors are highly but selectively effective in their impact on solid tumors. This session will examine the next wave of innovation in immunotherapies for leveraging knowledge of how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients.

MODERATOR: Jotin Marango, MD, PhD, Managing Director, Senior Research Analyst, ROTH Capital

PANELISTS: Lewis H. Bender, Chief Executive Officer, Intensity TherapeuticsSabine Chlosta, MD, PhD, Chief Medical Officer, Triumvira ImmunologicsGere diZerega, MD, Vice President of Clinical Affairs and Medical Director, NanOlogyEric Falcand, Vice President, Business Development & Licensing, Servier

Fireside Chats10:00-10:55 AM Nancy Thornberry

Chief Executive Officer, Kallyope

12:00-12:55 PM Geoff Meyerson Managing Partner and Co-Founder, Locust Walk

2:30-3:25 AM Jinzi J. Wu, PhD Founder, Chairman and Chief Executive Officer, Ascletis Pharma Inc.

Yasmeen Rahimi, PhD Managing Director and Senior Research Analyst, ROTH Capital

Mark Tang, PhD, MPH Managing Director, Good Health Capital

Sapna Srivastava, PhD

4 bio.org/CEO • #BIOCEO19

• Advances in Neuromuscular Disease Treatments11:00-11:55 AM

After a long era without progress, recent years have seen regulatory approvals of treatments for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), among other neuromuscular disorders. In particular, SMA is the most common genetic disorder leading to infant death in the world, and now has a first therapy that can slow disease progression, giving patients and families more time together. This session will examine the exciting pipeline of additional neuromuscular disease therapies, and what the underlying science is teaching across disease indications, amid a complicated reimbursement context where the shortage of effective treatments bears significant healthcare costs over time.

MODERATOR: Lynn O’Connor Vos, President and CEO, Muscular Dystrophy Association

PANELISTS: Murray Aitken, Executive Director, IQVIA Institute for Human Data ScienceAmanda Hadet-Philips, PhD, Scientific Portfolio Director, Muscular Dystrophy AssociationNader Yaghoubi, MD, PhD, President, Chief Executive Officer and Co-Founder,

PathMaker Neurosystems Inc. Brian K. Kaspar, PhD, Chief Scientific Officer, AveXis [invited]

• Navigating Payers’ Expectations for Value-Based Agreements1:30-2:25 PM

As biomedical innovation has developed advanced therapeutic modalities and prospective cures for ailments that previously had no comparable courses of treatment, the challenge of crafting sustainable reimbursement models has inspired a variety of value-based agreements. Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.

MODERATOR: Yasmeen Rahimi, PhD, Managing Director and Senior Research Analyst, ROTH Capital

PANELIST: Ron Philip, Chief Commercial Officer, Spark TherapeuticsRoger Longman, Chairman, Real Endpoints

• Attacking Biological Mechanisms of Aging to Extend Healthspan3:30-4:25 PM

A growing number of biopharma companies have responded to the emerging medical consensus that many of the individual ailments experienced by older people have underlying, connective biological causes. These companies are developing drugs in areas such as neurodegeneration, macular degeneration, arthritis, and similar highly prevalent diseases by pursuing novel mechanisms versus existing treatments. This session will discuss the frontier of science in extending the years of healthy aging and in which indications patients might first see progressive new therapies in clinical trials.

MODERATOR: Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research

PANELISTS: Grace Colón, Chief Executive Officer, InCarda Therapeutics Philippe Calais, Pharm.D, PhD, Chief Executive Officer, CohBarAna Maria Cuervo, MD, Co-Director, Institute on Aging,

Albert Einstein College of Medicine [invited]Charles S. Ryan, JD, PhD, Chief Executive Officer, NeurotropeSalim Syed, Managing Director, Senior Biotechnology Analyst,

Head of Biotechnology Research, Mizuho Securities USA LLC

5 bio.org/CEO • #BIOCEO19

• Market Outlook—Leveraging Market Corrections for M&A or IPOs4:30-5:45 PM

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors’ eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated. More than half those companies are trading below their IPO prices, however, complicating conditions for the next new offering. As interest rate worries, international trade disputes, and regulatory reimbursement uncertainty have increased, biopharma stock indexes have seen significant corrections. With historically high valuations experiencing sudden dips, M&A deal-making seems to have reignited with notable, multi-billion-dollar deals in recent weeks. This session will assemble market experts to discuss what forces continue to shape performance within the sector and what opportunities the market correction can reveal for investors and companies seeking resources to deliver the next wave of innovative therapies for patients.

MODERATOR: Sara Michelmore, Senior Vice President, Investor Relations, MacDougall Biomedical Communications

PANELISTS: Katherine Andersen, Senior Market Manager, Silicon Valley Bank (SVB)Noël Brown, Managing Director, Cantor FitzgeraldAndrew Gitkin, Managing Director, Piper JaffrayBrian Gleason, Managing Director, CitiGeoffrey Goodman, Managing Director, Wells Fargo SecuritiesPhilip Ross, Vice Chairman, J.P. MorganYaron Werber, Managing Director, Cowen

BIO’s One-on-One Partnering™ system is the interactive platform that allows you to increase your

productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

• Pre-schedule 30-minute private 1x1 meetings

• Source potential collaborations and funding opportunities with an international audience

• Communicate directly with prospective investors and C-level executives in biotech and pharma

• Search company and investor profiles for potential business partnerships

6 bio.org/CEO • #BIOCEO19

TUESDAY, FEBRUARY 12

• New Treatments for Diabetes and Obesity: Innovations for Chronic Diseases9:00-9:55 AM

BIO research on venture funding trends shows a long-term slowdown in overall investment in chronic diseases, despite their large patient populations, but with recent signs of hope in investor support for new treatments for diabetes and obesity. This session will detail those drug pipelines, which research approaches are convincing skeptical investors, as well as the sources of investor resistance, plus opportunities for streamlining high-cost clinical trials in these disease areas through application of digital technologies.

MODERATOR: Dave Thomas, Vice President, Industry Research, Emerging Companies, Biotechnology Innovation Organization (BIO)

PANELISTS: Dara Schuster, MD, Chief Executive Officer, T1D ExchangeBrian McVeigh, Chief Business Officer, Zafgen

Fireside Chats10:00-10:55 AM Jonathan Leff

Partner, Deerfield Management, Chairman, Deerfield Institute

12:00-12:55 PM Roger Crystal, MD Chief Executive Officer, Opiant Pharmaceuticals

3:00-3:55 PM Dr. Aoife Brennan Chief Executive Officer and Chief Medical Officer, Synlogic, Inc.

Annette Grimaldi Managing Director and Head of Life Sciences Investment Banking, BMO Capital Markets

Brandon Folkes Director, Cantor Fitzgerald

Raghuram Selvaraju, PhD Managing Director, Senior Healthcare Analyst, H.C. Wainwright and Co.

7 bio.org/CEO • #BIOCEO19

Did you know?2019 BIO CEO has a record share

of private company investors.

Royalty/Debt Financing 4%

Family Office15%

Angel Investing9%

Other Public Market20%Hedge/Mutual Funds

(PM, Buy-Side Research)21%

VC/Corporate VC 31%

Types of Investors

• Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?11:00-11:55 AM

The U.S. Department of Health and Human Services has proposed piloting an “International Pricing Index” (IPI) payment model to reduce reimbursement levels for the Centers for Medicare & Medicaid Services (CMS), as well as proposing other reforms to long-standing policies regarding commercialized medicines. In a year with a record number of new medicines being approved to reach patients in the United States, such reforms introduce significant uncertainty for many investors’ valuation models. This session will feature drug developers, investors, and policy experts to explain the resource allocation implications if these reforms proceed and risks of shrinking the pipelines of new medicines for years to come unless alternative approaches can be introduced.

MODERATOR: James Greenwood, President and CEO, Biotechnology Innovation Organization (BIO)

PANELISTS: Paul Lammers, MD, President and CEO, Triumvira Immunologics Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging ResearchPeter J. Pitts, President, Center for Medicine in the Public InterestDuane Schulthess, Managing Director, Vital Transformation Art Pappas, Managing Partner, Pappas CapitalErica Whittaker, PhD, Head of UCB Ventures, UCB Pharma

• Regulatory Changes to Cross-Border Investments: CFIUS and Biotech Deals1:00-1:55 PM

New national security regulations under the Foreign Investment Risk Review Modernization Act (FIRRMA) are changing the landscape for cross-border investments in biotechnology. In November 2018, new rules for a “pilot program” apply to foreign investors into U.S. companies who now need to file with the Committee on Foreign Investment in the United States (CFIUS) to approve covered transactions before entering licensing deals or other equity investments. This session will update market participants on the evolving national security review process and its impact on the biotechnology industry, as well as consider how additional rules may impact future business development and investment opportunities.

MODERATOR: Lisa Schaefer, Director, Tax & Financial Services Policy, Biotechnology Innovation Organization (BIO)

PANELISTS: Jun Bao, PhD, President and Chief Executive Officer, Impact TherapeuticsJoseph Benkert, Senior Advisor, Morrison & Foerster LLPJeff Farrah, General Counsel, National Venture Capital Association (NVCA)Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Group;

Regional Leader for BayHelix's NY/NJ/PA Chapters

8 bio.org/CEO • #BIOCEO19

• Removing Commercialization Barriers for New Antimicrobial Drugs2:00-2:55 PM

After years of sparse development of new antimicrobials, R&D incentive initiatives such as CARB-X and the GAIN Act have facilitated the entry of a new generation of antimicrobials into the pipeline, with several recent approvals over the past year. Unfortunately, difficult commercialization experiences of leaders in this space threaten to derail the momentum of the sector unless urgent action is taken. In response, the FDA has proposed the health care system consider a subscription model for the purchase of antibiotics by hospitals in an effort to increase the reliability of a return on investment in new antibiotics and avoid high-volume prescribing practices that would accelerate antimicrobial resistance. This session will include policy, antimicrobial developer, and investor perspectives on this issue to discuss the opportunities and challenges of business model changes and what short-term and long-term steps are needed to avoid a crisis described by the World Health Organization as a “post-antibiotic era where common infections and minor injuries can once again kill.”

MODERATOR: Gregory Frank, PhD, Director, Infectious Disease Policy, Biotechnology Innovation Organization (BIO)

PANELISTS: Heather Behanna, Board Director, EntasisCiara Kennedy, PhD, President and Chief Executive Officer, AmplyxKevin Outterson, Professor and Executive Director at CARB-X, Boston UniversityManos Perros, PhD, Chief Executive Officer, Entasis Therapeutics

• Are Record Levels of IPOs Still Disrupting M&A Deals?4:00-4:55 PM

In 2018, biotechs delivered a near-record year for public issuances. The attractive IPO market has however resulted in fewer M&A deals than prior years, with high pre-money IPO valuations for later-stage companies making it less enticing for them to accept early-exit offers. This has led to an M&A shift to focus on early-stage companies. How are changing valuations and exit options affecting venture investors? How are prospective buyers changing their deal terms? The session will examine the recent deal and market trends while highlighting the path forward amid a market with greatly increased volatility and reimbursement policy uncertainty.

MODERATOR: Lydia Ramsey, Senior Reporter, Business Insider

PANELISTS: John Chambers, President and Head of Investment Banking, H.C. Wainwright & Co.Jie D'Elia, PhD, Executive Director, Business Development Transactions, Bristol-Myers SquibbChris Garabedian, Chairman & CEO, XontogenyJames Healy, MD, PhD, Partner, Sofinnova InvestmentsDennis Purcell, Co-Founder, Aisling Capital

Did you know?2019 BIO CEO has investors from

18 different U.S. states under one roof.

9 bio.org/CEO • #BIOCEO19

2019 Presenting Companies*CardiovascularEspero BioPharmaInCarda TherapeuticsResverlogix Corp.Verseon

CNS/NeurologicalAnavex Life SciencesBioasis Technologies Inc.BioXcel TherapeuticsCox Biosciences LLCE-Scape BioEIP Pharma, Inc.Knopp BiosciencesNeuroRxNewron Pharmaceuticals SpANoNO Inc.ORYZONOtsuka PharmaceuticalPAION AGSerina Therapeutics, Inc.Tonix Pharmaceuticals Holding Corp.Trevena, IncVallon Pharmaceuticals VistaGen Therapeutics, Inc.Zynerba Pharmaceuticals

DermatologyAzitra Inc.

DiagnosticsBioMarker Strategies, LLCGenes2me LLPInterpace DiagnosticsOncoCyte

Digital HealthCongenica LtdLumme Inc

GastrointestinalCancer Prevention PharmaceuticalsLandos BiopharmaMirum PharmaceuticalsSynthetic Biologics, Inc.

Gene/Cell TherapyAmerican Gene TechnologiesBrainstorm Cell TherapeuticsCesca Therapeutics Inc.Eloxx PharmaceuticalsFibrocell Science, Inc.MeiraGTx

ImmunologyAbcuro, Inc.aTyr Pharma, Inc.

INmune BioImmunic AGImmunSYS, Inc.

Infectious DiseasesAmplyx Pharmaceuticals Inc.CytoDyn Inc.Summit TherapeuticsVenatoRx Pharmaceuticals

Medical DevicesArch Therapeutics, Inc.CytoSorbentsFemeda Ltd

Metabolic DiseasesCohBar, Inc.SERAXIS INC.

Multiple TherapeuticsAlnylam Pharmaceuticals LifeEDITLyndra IncQ BioMed IncSirnaomics,Inc

Non-Profit/Patient Advocacy GroupNational Health Council Patient-Centered

Health Care Acceleratorr

OncologyActinium Pharmaceuticals, Inc.AIVITA BiomedicalAUM BiosciencesCASI Pharmaceuticals, Inc.CEL-SCI CorporationCellectar BiosciencesCue BiopharmaCuris, IncCyclacel Pharmaceuticals, Inc.ExicureGreenwich LifeSciencesHeat Biologics, Inc.Immunicum ABImmunoMet TherapeuticsImmunomic Therapeutics, Inc.IMV Inc.Infinity Pharmaceuticals Kleo PharmaceuticalsMaxCyte, Inc.Oncolytics Biotech Inc.Onconova Therapeutics, Inc.OxSonics LimitedPropanc Biopharma Inc.Salarius PharmaceuticalsSapience TherapeuticsSATOR Therapeutics LLC

SELLAS Life Sciences Group, Inc.Senti BiosciencesSutro Biopharma, Inc.Tarveda Therapeutics, Inc Trovagene OncologyVyriad, Inc.Zenith Epigenetics

OphthalmologyEyeGate Pharmaceuticals, Inc.Nemus BiosciencesNicox SAOcuMedic, Inc.Oxurion NVOyster Point Pharma, Inc.

Orphan/Rare DiseasesArcturus TherapeuticsCatalyst BiosciencesCatalyst Pharmaceuticals, Inc. Children's Tumor FoundationFulcrum TherapeuticsLung Therapeutics

OtherRockwell Medical, IncSelect Greater Philadelphia

Platform for TherapeuticsAnima Biotech Inc.Aquestive TherapeuticsOramed PharmaceuticalsSecond Genome, Inc

Regenerative MedicineAspect BiosystemsCaladrius Biosciences, IncCarmell TherapeuticsSpinalCyte, LLC

Reproductive/Sexual HealthDaré BioscienceUrigen Pharmaceuticals, Inc.

RespiratoryProterixBio, IncTenax Therapeutics, Inc.Verona Pharma

Tools/Drug Develoopment Support TechAbMax Biotechnology CO., LTDPrecision NanoSystems

*as of January 30, 2019

10 bio.org/CEO • #BIOCEO19

2019 Participating Investors*3E BioventuresAbbVie Accelerator Life Science PartnersAceras BioMedicalAcuris PartnersAdjuvant CapitalAE Capital Aegis Capital Corp.Affinity Asset AdvisorsAgent CapitalAIG Global Investment CorporationAisling CapitalAleph CapitalAlignment VenturesAlpha BioLabsAlpha Blue Ocean Advisors Alpha HoldingsAndreessen HorowitzAperture Venture PartnersAracle CapitalArch Venture PartnersAristar CapitalArix BioscienceAshford Capital ManagementAspire CapitalAsset Management VenturesAstute CapitalATEL Ventures IncAthena Bio VenturesAtheneos VenturesATWAurora Capital, LLCB. Riley FBRBand of AngelsBank of America Merrill Lynch

Global ResearchBE CapitalBeacon CapitalBerenberg Capital MarketsBHP CapitalBIMA CapitalBioadvance-The Biotech Greenhouse

Corp of SoutheasBioIdeationsBioInnovation CapitalBiondo Investment AdvisorsBioSense GlobalBiotech Alliances InternationalBioventure PartnersBlack Diamond Advisors BMO Capital Markets (U.S.)BOHE Angel FundBojian CapitalBorex CapitalBridge BankBrock Capital GroupBrookline Capital MarketsBrothers & Partners EuropeBryan, Garnier & CoBTIGCapgenic AdvisorsCato BioVenturesCaxton Alternative Management LPCB1 CapitalC-Bridge CapitalCEC Capital GroupCedrus InvestmentsChardan Capital MarketsCharlestown CapitalChronon CapitalCJ Seligman & Co.Cowen and CompanyCowen Healthcare InvestmentsCowin CapitalCrown Point GroupCRVCS McKeeCSC LeasingCTI Life SciencesCTTQ Phamaceutical GroupDabar Investment Associates

Dec Family VenturesDeca VenturesDelos Capital Partners/Delos Life SciencesDeltec BankDHVCDiamondback Capital ManagementDouglas C. Lane & AssociatesDynamk CapitalE Squared Capital Management, LLCEaston CapitalEfrat InvestmentsEntech BioEsousa HoldingsEverpine CapitalEVOLUTION Life Science PartnersFannin Innovation StudioFC Capital ManagementFiera CapitalFirst Island CapitalForesite Capital ManagementFortress BiotechFortunatus CapitalFosun PharmaFoxhill Asset ManagementGCF Family OfficeGE VenturesGenoa VenturesGHS InvestmentsGlobal Corporate FinanceGlobal Health Investment FundGlobal Source VenturesGolden SeedsGoldwater Asset ManagementGood Health CapitalGorlin CompaniesGradus/ RSJ Private EquityGreenSky CapitalGrey Sky Venture PartnersGriffin SecuritiesGuggenheimH.C. Wainwright & CompanyH.I.G. BioHealth PartnersH.I.G. CapitalHarbin Pharmaceutial GroupHarborview CapitalHartford Financial MgmtHayfin Capital ManagementHCMHealthCare Royalty PartnersHelicase VentureHelix ManagementHemi VenturesHercules CapitalHI Investors CapitalHood River Capital ManagementHudson East CapitalHumanwell Healthcare GroupIaso VenturesIDG Capital PartnersIllumina VenturesImage Analysis GroupINKEF CapitalInMed PharmaceuticalsIntegriumJafco Co.JBS Healthcare VenturesJefferiesJina VenturesJohnston AssociatesJP MorganKalka Fund LPKatalyst SecuritiesKnoll Capital ManagementL1 CapitalL2 CapitalLadenburg ThalmannLaidlaw & CompanyLandmark AngelsLifeScience EquityPartnersLifeTech CapitalLilly Asia Ventures

Lincoln Park CapitalLivingstonLocust WalkLongitude CapitalLord AbbettLSWorksLumira CapitalMadison Square CapitalMagid Family OfficeMaxim GroupMaxim Merchant CapitalMayTech Global InvestmentsMAZ Capital AdvisorsMedexplore VenturesMediqventuresMEDX Ventures GroupMerlin NexusMid Atlantic Bio AngelsMilitia Hill VenturesMithril Capital ManagementMitsui & Co. Global InvestmentMizuho BankMizuho SecuritiesMomentum BiotechMontrose Capital PartnersMossrock CapitalMP Healthcare Venture ManagementMPM CapitalMSAB CapitalMSQ VenturesMuirfield Capital.Murdock Capital Partners CorporationMV Corp ServicesMVP Capital PartnersNauVista Capital ManagementNCL Technology VenturesNeedham & CompanyNeurotropeNew Harbor Venture PartnersNew Science VenturesNew York City Economic

Development CorporationNGN CapitalNJAngelsNoble Equity FundNordcon CapitalNorthern Light Venture CapitalNovatio VenturesNSIPNYC Medtech/PerselsonNYS Innovation VC FundOCVOlive Tree CapitalOncolytics BiotechOppenheimer & CoOpti Capital ManagementOrchard View Capital Advisors LPOrion Consultoria FinanceiraOtsuka Pharmaceutical Co.Oxford FinancePappas CapitalPark Ave. Capital Management InternationalPaulson Investment CompanyPeak One InvestmentsPeter B. Cannell & Co.Petrichor Healthcare Capital ManagementPfizerPharmakon AdvisorsPipeline AngelsPipeline CapitalPiper Jaffray VenturesPowder GatePrevail PartnersPrinceton BiopharmaPromethean Capital GroupQiming Venture PartnersQuan CapitalRadius FinancialRed Hook Asset ManagementRemsen Investors LPRepertoire Asset Management

RHK CapitalRolinROTH Capital PartnersRoyalty Pharma ManagementSanten Pharmaceutical Co.Sarasota InvestmentsSatter Medical Technology PartnershipSBP ManagementSC FundamentalScopus VenturesSecond Line Capital MgmtSeroba Life SciencesSerrado CapitalShanghai Fosun Pharmaceutical (Group) Co.Shaw Strategic CapitalShenzhen Salubris Pharmaceuticals Co,ltdSimrx AdvisorsSio Capital ManagementSofinnova VenturesSorrento TherapeuticsSpecial Situations FundsSquare 1 BankStarLink CapitalSternAegis VenturesSunTrust Robinson HumphreySurveyor CapitalSV InvestmentSymphonia PartnersTaglich Private EquityTalfinium InvestmentsTanaka Capital ManagementTap AdvisorsTerra Magnum Capital PartnersThe Anson GroupThe Astrologers FundThe Carlyle GroupThe Leukemia & Lymphoma SocietyThe Lind PartnersThe Mark Foundation for Cancer ResearchTransPacific Venture Capital PartnersTrevie CapitalTryphon Capital AdvisorsTurret Capital MangementUnum CapitalUpstream PartnersV2m Life Sciences FundVector Resource FundsVersant VenturesVida VenturesViva Biotech HoldingsVivo CapitalW Global Capital Ltd/International

Capital ManagementWallachbeth CapitalWatermill Asset ManagementWBB Asset ManagementWBB Securities, LLCWells FargoWestPark CapitalWexford CapitalWhitwell PartnersWolf Capital ManagementWolpert AssociatesXeraya Capital Life VentureYA GlobalYale UniversityYlLGA Management ServicesYonjin CapitalYoung America CapitalYuhan USAZacks SCRZenity Holdings New York

*as of January 30, 2019

11 bio.org/CEO • #BIOCEO19

2019 Participating Companies*AbcuroAbMax Biotechnology Co.Acme Acquist TherapeuticsActinium PharmaceuticalsAdociaAdventHealthAffigenAffimed N.V.AiVita BiomedicalAlliance for Aging ResearchAlliance Global PartnersAlloy TherapeuticsAlnylam PharmaceuticalsAlpha Cancer TechnologiesAltimmuneAmerican Gene Technologies InternationalAmerican Laboratory Trading (ALT)Amplyx PharmaceuticalsAnavex Life Sciences Corp.AnGesAnima BiotechAntengene Corporation Co.Aon Risk SolutionsAptorum Group LimitedAquestive TherapeuticsArbor PharmaceuticalsArch TherapeuticsArcturus TherapeuticsAscletis PharmaAspect BiosystemsAstellas Pharma USAtomwiseaTyr PharmaAUMAustradeAvid BioservicesAzitraBerlin Partner GmbHBIABio GuestBioasis TechnologiesBiocomBioMarker StrategiesBio-Path HoldingsBiotechgate/Venture ValuationBioVaxys BioVersys AGBioxceed Innovation HubBioXcel TherapeuticsBlaise Group InternationalBloom ScienceBMO Capital MarketsBoehringer IngelheimBolder BiotechnologyBonneville LabsBrainstorm Cell TherapeuticsBrandenburg InvestBristol-Myers Squibb CompanyBusiness InsiderCaladrius BiosciencesCambridge Gene Therapy LimitedCanalis PharmaceuticalsCancer Prevention PharmaceuticalCancer Research & Biostatistics (CRAB)Cantor Fitzgerald & CompanyCARB-XCarmell TherapeuticsCASI PharmaceuticalsCatalyst BiosciencesCatalyst PharmaceuticalsCelgene CorporationCell Care TherapeuticsCellectar BiosciencesCEL-SCI CorporationCenter for Biocatalysis

and Bioprocessing - University of IowaCesca TherapeuticsCG PharmaceuticalsChildren's Tumor FoundationCity of PhiladelphiaClarivate Analytics

Clinical Network Services (CNS) Pty co.don AGCohBarColumbia UniversityCongenicaConsulate General of LithuaniaConSynance TherapeuticsContraFect CorporationCortellis / Calrivate AnalyticsCowen and CompanyCox BiosciencesCSPC PharmaCue BiopharmaCurisCyclacel PharmaceuticalsCytodynCytori TherapeuticsCytoSorbentsDaré BioscienceDeerfield Management Company LPDelaware Innovation SpaceDiaMedica TherapeuticsDyadic InternationalEditas MedicineEIP PharmaEli Lilly and CompanyEloxx PharmaceuticalsELS SolutionsEnGeneICEntasis TherapeuticsEpiVax OncologyE-Scape BioEspero BioPharmaEvaluateEVOQ TherapeuticsExicureEyeGate PharmaceuticalsFemtobiomedFibrocell ScienceFormula PharmaceuticalsFoundation for Prader Willi ResearchFreeMind GroupFulcrum TherapeuticsGalimedix TherapeuticsGedeon Richter PlcGenes2meGila TherapeuticsGlobal Business ReportsGovernment of VictoriaGreater Zurich Area AgGreek Trade Office at the Consulate General

of Greece in New YorkGreenwich LifeSciencesH.C. Wainwright & CompanyHeat BiologicsHelix BioPharma Corp.HemostemixHitech HealthI-APCELLICON Plc.ImcyseImmBioImmunic TherapeuticsImmunicum ABImmunoMet TherapeuticsImmunomic TherapeuticsImmunoPrecise AntibodiesImmunSYSImpact TherapeuticsIMVInCarda TherapeuticsIndegeneInfinity PharmaceuticalsInMed PharmaceuticalsINmune BioIntensity TherapeuticsInteRNA Technologies B.V.Interpace Diagnostics GroupInvestorInvirsaIota BiosciencesIQVIA

Japan External Trade Organization (JETRO)JP Morgan SecuritiesKallyopeKissei AmericaKitov PharmaceuticalsKleo PharmaceuticalsKnopp BiosciencesKorea Drug Development Fund (KDDF)KOTRALandos BiopharmaLantern PharmaLaunchBioLead PharmaLeading BioSciencesLifeEDITLongeveronLummeLung TherapeuticsLyndraLyonbiopoleMacDougallMarcumMarizymeMaryland Life SciencesMaxCyteMedical Developments International LimitedMedicenna TherapeuticsMeiraGTxMetrioPharm AGMilliporeSigmaMirum PharmaceuticalsMitsubishi Tanabe Pharma CorporationMorrison & FoersterMuscular Dystrophy Association (MDA)NanOlogyNational Health CouncilNational Venture Capital AssociationNemus BioscienceNeuroRxNeuroTrauma SciencesNew Enterprise Associates (NEA)New Orleans Business AllianceNew York BIONewron Pharmaceuticals, SpANewYorkBIONicOx, SANikon InstrumentsNoNONovos Growth PartnersNS PharmaNucleus NetworkOcuMedicOncoCyte CorporationOncolytics BiotechOnconova TherapeuticsOncoSec MedicalOpiant PharmaceuticalsOramed PharmaceuticalsOrpherisOryzon Genomics, S.A.Otsuka Pharmaceutical Co.OxSonics TherapeuticsOxurion NVOyster Point PharmaceuticalsPAION AGPanorama MedicineParas Biopharmaceuticals Finland OypH PharmaPharmaDirectionsPhio Pharmaceuticals CorporationPipeline TherapeuticsPiper Jaffray & Co.POP BiotechnologiesPrecision NanoSystemsProbiodrug AGProcarta BiosystemsPropanc BiopharmaProteina Co.ProterixBioQ BioMedRapafusyn PharmaceuticalsRecardio

Redhill BiopharmaReForm BiologicsReglageneRegrow BiosciencesReneo PharmaceuticalsResverlogix CorporationRhythm BiosciencesRockwell MedicalROTH Capital PartnersSalarius PharmaceuticalsSamyang Biopharmaceuticals CorporationSanofiSapience TherapeuticsSATOR TherapeuticsSchonfeld StrategicScilex PharmaceuticalsScynexisSea4UsSecond GenomeSelect Greater PhiladelphiaSellas Life Sciences GroupSEngine Precision MedicineSenti BiosciencesSeraxisSerina TherapeuticsServierShareVaultSIGA TechnologiesSilk Road TherapeuticsSilurian PharmaceuticalsSirnaomicsSofinnova VenturesSpark TherapeuticsSpinalCyteSummit Therapeutics plcSutro BiopharmaSwiss Business Hub USASynDevRxSyneos HealthSynlogicSynthetic BiologicsT1D ExchangeTarveda TherapeuticsTenax TherapeuticsThe Cure BVThe University of ChicagoTimmune BiotechTokyo Stock ExchangeTONIX PharmaceuticalsTorreyaTrican Biotechnology Co.Triumvira Immunologics USATrovaGeneUCB VenturesUnicycive TherapeuticsUniversity of Texas, MD Anderson

Cancer CenterUrigen PharmaceuticalsValentech PharmaVallon PharmaVBI VaccinesVenatoRx PharmaceuticalsVerona PharmaVerseon CorporationVistaGen TherapeuticsVital TransformationVWR InternationalVyome TherapeuticsVyriadWells FargoWilmerHaleYiviva / YaleZafgenZynerba Pharmaceuticals

*as of January 30, 2019

12 bio.org/CEO • #BIOCEO19

SponsorsDOUBLE HELIX SPONSORS

SUPPORTING BANK SPONSORS

CONFERENCE SPONSORS

MEDIA PARTNERS

SUPPORTING ORGANIZATIONS

LOCAL CO-HOST

13 bio.org/CEO • #BIOCEO19

2019 Advisory Committee

James AntonopoulosManaging Director, Co-Head of Healthcare Investment BankingROTH Capital Partners

Ari Nowacek, MD, PhDPrincipalARCH Venture Partners

Jonathan LeffPartnerDeerfield ManagementChairmanDeerfield Institute

Sapna Srivastava, PhDPrior Chief Financial Officer and Chief Strategy OfficerAbide Therapeutics

Janice BourqueManaging Director, Life SciencesHercules Technology Growth Capital

Timothy O’Connor, PhDExecutive Vice PresidentThe Rockefeller University

Jim MolloyManaging Director, Equity Research, Biotechnology & Specialty PharmaceuticalsAlliance Global Partners

Marco Taglietti, MDPresident and Chief Executive OfficerSCYNEXIS

Jie D’Elia, PhDExecutive Director, Business Development TransactionsBristol-Myers Squibb

Dennis J. PurcellFounder and Senior AdvisorAisling Capital

Bibhash Mukhopadhyay, PhDPrincipalNew Enterprise Associates

Lynn O’Connor VosPresident and CEOMuscular Dystrophy Association

John ChambersPresident and Head of Investment BankingH.C. Wainwright & Co.

Susan Peschin, MHSPresident and Chief Executive OfficerAlliance for Aging Research

William H. McMullanManaging DirectorThe Carlyle Group

Nassim Usman, PhDPresident and Chief Executive OfficerCatalyst Biosciences

Anna Kazanchyan, MDFounder & CEOSaghmos Therapeutics

Stephen RitochChairman and Chief Executive OfficerBlaise Group International

Kimberly NearingManaging Director, Head of Life SciencesCedrus GroupRegional Leader for BayHelix’s NY/NJ/PA Chapters

Scott WeinerPartnerPappas Capital

14 bio.org/CEO • #BIOCEO19

Registration & Housing InformationBIO offers a number of ways to conference attendees to save money on their registration fees.

Discounted rates apply to the following:

• Companies bringing more than three employees.

• Academic, government and non-profit institutions.

• Service providers suppliers.

Qualified institutional and venture investors are eligible for complimentary registration.

BIO has a block of discounted hotel rooms for BIO CEO attendees. To take advantage of this special rate, contact the hotel no later than January 25th.

New York Marriott Marquis1535 Broadway, New York

212.398.1900

Contact BIO Registration

Email: registration@bio.org

Telephone: +1.202.962.6655

15 bio.org/CEO • #BIOCEO19